 |
Hanmi Pharmaceutical and OCI headquarters |
[Alpha Biz=(Chicago) Reporter Kim Jisun] Lim Joo-hyun, president of Hanmi Pharmaceutical, said, "When the integration with OCI is completed, we will ask OCI Holdings to deposit shares of major shareholders of Hanmi Science without disposal over the next three years."
"The premise of the integration is to continue to leave the management of the Hanmi Group to the existing management instead of transferring the shares of my mother and I without a premium," CEO Lim said in a statement on the 24th. "There have been many suggestions to guarantee a premium in family shares along with management rights, but I did not want to give up the Hanmi Group's tradition of developing new drugs."
"If it proceeds as the brothers claim, the brothers' shares are likely to be on the market soon with a premium, which will directly lead to a violation of the rights and interests of Hanmi Group and ordinary shareholders," CEO Lim said.
He also asked for an alternative to the inheritance tax issue and Hanmi Pharmaceutical Group's R&D investment. President Lim said, "We hope the brothers will reveal the actual and specific alternatives and the source of the funds for the remaining inheritance tax."
The Hanmi Group will hold a press conference of President Lim Joo-hyun at the Park Hall on the second floor of the Hanmi Tower in Songpa, Seoul, at 4 p.m. on the 25th. Ahead of Hanmi Science's regular shareholders' meeting on the 28th, Hanmi Pharmaceutical Group is facing a series of confrontations between mother and daughter who are pushing for integration with their brothers who oppose the merger.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
